Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Legal Action !!!

<< Previous

Bullboard Posts

Next >>

Comment by SeeDonRunon Oct 02, 2021 9:47pm

141 Views

Post# 33958148

RE:RE:Legal Action !!!

Hamstock wrote: Am I missing any PR after Sep 16? The latest one telling us right to global sell of Biozeus product! The one before, they talked about completion of phase I on Q1 of 2022! Weired.....

Yes. This one from yesterday.

https://www.stockwatch.com/News/Item/Z-C!CLAS-3146964/C/CLAS

Have to keep your ear close to the ground on this stock as they often don't post news releases in the clear so you need to either come here, or CEO or on the Facebook Claritas Investors site.

You must have milions of dollars invested as it's going to cost that to mount a law suit. When you pay out your retainer let me know so I can jump on board to help sue a company that doesn't have any money.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec